nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—EPHA2—pulmonary artery—vascular cancer	0.0597	0.191	CbGeAlD
Nilotinib—MAPK8—blood vessel—vascular cancer	0.0292	0.0935	CbGeAlD
Nilotinib—TIE1—blood vessel—vascular cancer	0.0253	0.081	CbGeAlD
Nilotinib—MAPK14—blood vessel—vascular cancer	0.0185	0.0593	CbGeAlD
Nilotinib—EPHB4—blood vessel—vascular cancer	0.0176	0.0563	CbGeAlD
Nilotinib—EPHA2—blood vessel—vascular cancer	0.0172	0.0552	CbGeAlD
Nilotinib—TEK—blood vessel—vascular cancer	0.0168	0.0538	CbGeAlD
Nilotinib—CDC42BPB—cardiac atrium—vascular cancer	0.0131	0.0418	CbGeAlD
Nilotinib—KIT—blood vessel—vascular cancer	0.0122	0.039	CbGeAlD
Nilotinib—PDGFRB—blood vessel—vascular cancer	0.0119	0.0381	CbGeAlD
Nilotinib—TIE1—cardiac atrium—vascular cancer	0.0102	0.0328	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—vascular cancer	0.00813	0.026	CbGeAlD
Nilotinib—CA3—cardiac atrium—vascular cancer	0.00803	0.0257	CbGeAlD
Nilotinib—CA14—cardiac atrium—vascular cancer	0.00729	0.0233	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—vascular cancer	0.00711	0.0227	CbGeAlD
Nilotinib—LYN—RANKL/RANK Signaling Pathway—MITF—vascular cancer	0.00701	0.0102	CbGpPWpGaD
Nilotinib—EPHA2—cardiac atrium—vascular cancer	0.00697	0.0223	CbGeAlD
Nilotinib—TEK—cardiac atrium—vascular cancer	0.0068	0.0218	CbGeAlD
Nilotinib—MAPK14—p38 signaling mediated by MAPKAP kinases—TSC2—vascular cancer	0.00669	0.00972	CbGpPWpGaD
Nilotinib—MAPK14—RANKL/RANK Signaling Pathway—MITF—vascular cancer	0.00664	0.00966	CbGpPWpGaD
Nilotinib—LYN—Kit receptor signaling pathway—MITF—vascular cancer	0.00662	0.00963	CbGpPWpGaD
Nilotinib—EPHB6—cardiac atrium—vascular cancer	0.0065	0.0208	CbGeAlD
Nilotinib—KIT—C-MYB transcription factor network—CD34—vascular cancer	0.00643	0.00936	CbGpPWpGaD
Nilotinib—MAPK14—Kit receptor signaling pathway—MITF—vascular cancer	0.00628	0.00913	CbGpPWpGaD
Nilotinib—ABL1—Regulation of retinoblastoma protein—MITF—vascular cancer	0.00603	0.00877	CbGpPWpGaD
Nilotinib—MAPK14—Regulation of retinoblastoma protein—MITF—vascular cancer	0.00574	0.00835	CbGpPWpGaD
Nilotinib—MAPK8—Wnt Signaling Pathway Netpath—TSC2—vascular cancer	0.00569	0.00828	CbGpPWpGaD
Nilotinib—MAP2K5—cardiac atrium—vascular cancer	0.00556	0.0178	CbGeAlD
Nilotinib—MAPK14—FSH signaling pathway—TSC2—vascular cancer	0.00547	0.00795	CbGpPWpGaD
Nilotinib—CSF1R—cardiac atrium—vascular cancer	0.00543	0.0174	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—vascular cancer	0.00481	0.0154	CbGeAlD
Nilotinib—MAPK14—Monoamine Transport—TSC2—vascular cancer	0.00477	0.00694	CbGpPWpGaD
Nilotinib—ABL1—cardiac atrium—vascular cancer	0.00429	0.0137	CbGeAlD
Nilotinib—MAP2K5—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.00376	0.00547	CbGpPWpGaD
Nilotinib—BRAF—mTOR signaling pathway—TSC2—vascular cancer	0.00371	0.0054	CbGpPWpGaD
Nilotinib—CA4—cardiac atrium—vascular cancer	0.00352	0.0113	CbGeAlD
Nilotinib—CA3—Metabolism—WWTR1—vascular cancer	0.00344	0.005	CbGpPWpGaD
Nilotinib—EPHA2—Direct p53 effectors—TSC2—vascular cancer	0.00339	0.00493	CbGpPWpGaD
Nilotinib—MAP4K1—Insulin Signaling—TSC2—vascular cancer	0.00333	0.00484	CbGpPWpGaD
Nilotinib—ABCB1—blood vessel—vascular cancer	0.0033	0.0106	CbGeAlD
Nilotinib—BRAF—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.00312	0.00454	CbGpPWpGaD
Nilotinib—PDGFRB—Validated targets of C-MYC transcriptional repression—TSC2—vascular cancer	0.00299	0.00435	CbGpPWpGaD
Nilotinib—CA2—cardiac atrium—vascular cancer	0.00292	0.00935	CbGeAlD
Nilotinib—KIT—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00273	0.00398	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.00269	0.00391	CbGpPWpGaD
Nilotinib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00259	0.00376	CbGpPWpGaD
Nilotinib—MAPK8—BDNF signaling pathway—TSC2—vascular cancer	0.00252	0.00366	CbGpPWpGaD
Nilotinib—KIT—PI-3K cascade—TSC2—vascular cancer	0.00246	0.00358	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.00242	0.00352	CbGpPWpGaD
Nilotinib—KIT—PI3K/AKT activation—TSC2—vascular cancer	0.0024	0.0035	CbGpPWpGaD
Nilotinib—MAP2K5—BDNF signaling pathway—TSC2—vascular cancer	0.0024	0.00348	CbGpPWpGaD
Nilotinib—KIT—GAB1 signalosome—TSC2—vascular cancer	0.00239	0.00347	CbGpPWpGaD
Nilotinib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00233	0.00339	CbGpPWpGaD
Nilotinib—PDGFRA—PI-3K cascade—TSC2—vascular cancer	0.00233	0.00339	CbGpPWpGaD
Nilotinib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00233	0.00339	CbGpPWpGaD
Nilotinib—MAPK8—Insulin Signaling—TSC2—vascular cancer	0.00232	0.00337	CbGpPWpGaD
Nilotinib—PDGFRA—PI3K/AKT activation—TSC2—vascular cancer	0.00228	0.00331	CbGpPWpGaD
Nilotinib—PDGFRA—GAB1 signalosome—TSC2—vascular cancer	0.00226	0.00328	CbGpPWpGaD
Nilotinib—CA14—Metabolism—WWTR1—vascular cancer	0.00222	0.00322	CbGpPWpGaD
Nilotinib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00221	0.00321	CbGpPWpGaD
Nilotinib—MAP2K5—Insulin Signaling—TSC2—vascular cancer	0.0022	0.0032	CbGpPWpGaD
Nilotinib—CA6—Metabolism—WWTR1—vascular cancer	0.00216	0.00314	CbGpPWpGaD
Nilotinib—MAPK8—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00214	0.00311	CbGpPWpGaD
Nilotinib—PDGFRB—PI-3K cascade—TSC2—vascular cancer	0.0021	0.00305	CbGpPWpGaD
Nilotinib—PDGFRB—PI3K/AKT activation—TSC2—vascular cancer	0.00205	0.00298	CbGpPWpGaD
Nilotinib—PDGFRB—GAB1 signalosome—TSC2—vascular cancer	0.00203	0.00296	CbGpPWpGaD
Nilotinib—CA7—Metabolism—WWTR1—vascular cancer	0.00202	0.00293	CbGpPWpGaD
Nilotinib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00199	0.00289	CbGpPWpGaD
Nilotinib—BLK—B Cell Activation—TSC2—vascular cancer	0.00198	0.00288	CbGpPWpGaD
Nilotinib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00195	0.00283	CbGpPWpGaD
Nilotinib—CA3—Metabolism—HBA1—vascular cancer	0.00193	0.0028	CbGpPWpGaD
Nilotinib—BRAF—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00191	0.00278	CbGpPWpGaD
Nilotinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00187	0.00272	CbGpPWpGaD
Nilotinib—CA12—Metabolism—WWTR1—vascular cancer	0.00187	0.00272	CbGpPWpGaD
Nilotinib—MAPK11—Insulin Signaling—TSC2—vascular cancer	0.00185	0.00268	CbGpPWpGaD
Nilotinib—KIT—Signaling by SCF-KIT—TSC2—vascular cancer	0.00184	0.00268	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—CD34—vascular cancer	0.00184	0.00268	CbGpPWpGaD
Nilotinib—BRAF—Signaling by FGFR—TSC2—vascular cancer	0.00181	0.00263	CbGpPWpGaD
Nilotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.0018	0.00262	CbGpPWpGaD
Nilotinib—KIT—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00176	0.00256	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by SCF-KIT—TSC2—vascular cancer	0.00174	0.00253	CbGpPWpGaD
Nilotinib—KIT—Signaling by ERBB4—TSC2—vascular cancer	0.00173	0.00252	CbGpPWpGaD
Nilotinib—BRAF—Signaling by FGFR in disease—TSC2—vascular cancer	0.00169	0.00245	CbGpPWpGaD
Nilotinib—LCK—PI-3K cascade—TSC2—vascular cancer	0.00169	0.00245	CbGpPWpGaD
Nilotinib—HCK—Disease—WWTR1—vascular cancer	0.00168	0.00245	CbGpPWpGaD
Nilotinib—PDGFRA—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00167	0.00243	CbGpPWpGaD
Nilotinib—KIT—Downstream signal transduction—TSC2—vascular cancer	0.00166	0.00241	CbGpPWpGaD
Nilotinib—KIT—Signaling by FGFR—TSC2—vascular cancer	0.00165	0.0024	CbGpPWpGaD
Nilotinib—LCK—PI3K/AKT activation—TSC2—vascular cancer	0.00165	0.00239	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by ERBB4—TSC2—vascular cancer	0.00164	0.00239	CbGpPWpGaD
Nilotinib—KIT—Signaling by ERBB2—TSC2—vascular cancer	0.00164	0.00238	CbGpPWpGaD
Nilotinib—LCK—GAB1 signalosome—TSC2—vascular cancer	0.00163	0.00237	CbGpPWpGaD
Nilotinib—KIT—DAP12 signaling—TSC2—vascular cancer	0.00163	0.00237	CbGpPWpGaD
Nilotinib—KIT—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00161	0.00234	CbGpPWpGaD
Nilotinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.0016	0.00232	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by SCF-KIT—TSC2—vascular cancer	0.00157	0.00228	CbGpPWpGaD
Nilotinib—PDGFRA—Downstream signal transduction—TSC2—vascular cancer	0.00157	0.00228	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by FGFR—TSC2—vascular cancer	0.00156	0.00227	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by ERBB2—TSC2—vascular cancer	0.00155	0.00226	CbGpPWpGaD
Nilotinib—PDGFRA—DAP12 signaling—TSC2—vascular cancer	0.00154	0.00225	CbGpPWpGaD
Nilotinib—LYN—Signaling by SCF-KIT—TSC2—vascular cancer	0.00154	0.00224	CbGpPWpGaD
Nilotinib—KIT—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00153	0.00223	CbGpPWpGaD
Nilotinib—KIT—DAP12 interactions—TSC2—vascular cancer	0.00153	0.00223	CbGpPWpGaD
Nilotinib—KIT—Signaling by FGFR in disease—TSC2—vascular cancer	0.00153	0.00223	CbGpPWpGaD
Nilotinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00152	0.00221	CbGpPWpGaD
Nilotinib—KIT—Signaling by EGFR—TSC2—vascular cancer	0.00152	0.00221	CbGpPWpGaD
Nilotinib—KIT—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00151	0.00219	CbGpPWpGaD
Nilotinib—MAPK11—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00151	0.00219	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.0015	0.00218	CbGpPWpGaD
Nilotinib—KIT—Signaling by PDGF—TSC2—vascular cancer	0.0015	0.00218	CbGpPWpGaD
Nilotinib—BRAF—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00149	0.00217	CbGpPWpGaD
Nilotinib—CA4—Metabolism—WWTR1—vascular cancer	0.00149	0.00217	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by ERBB4—TSC2—vascular cancer	0.00148	0.00215	CbGpPWpGaD
Nilotinib—MAPK8—Signaling by NGF—TSC2—vascular cancer	0.00146	0.00212	CbGpPWpGaD
Nilotinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00145	0.00211	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by FGFR in disease—TSC2—vascular cancer	0.00145	0.00211	CbGpPWpGaD
Nilotinib—PDGFRA—DAP12 interactions—TSC2—vascular cancer	0.00145	0.00211	CbGpPWpGaD
Nilotinib—ABL1—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00145	0.00211	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by EGFR—TSC2—vascular cancer	0.00144	0.00209	CbGpPWpGaD
Nilotinib—MAPK14—BDNF signaling pathway—TSC2—vascular cancer	0.00143	0.00208	CbGpPWpGaD
Nilotinib—CA2—Metabolism—WWTR1—vascular cancer	0.00143	0.00208	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00143	0.00208	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by PDGF—TSC2—vascular cancer	0.00142	0.00207	CbGpPWpGaD
Nilotinib—KIT—B Cell Activation—TSC2—vascular cancer	0.00142	0.00207	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signal transduction—TSC2—vascular cancer	0.00141	0.00205	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by FGFR—TSC2—vascular cancer	0.0014	0.00204	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by ERBB2—TSC2—vascular cancer	0.0014	0.00203	CbGpPWpGaD
Nilotinib—PDGFRB—DAP12 signaling—TSC2—vascular cancer	0.00139	0.00202	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling by NGF—TSC2—vascular cancer	0.00138	0.00201	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00137	0.00199	CbGpPWpGaD
Nilotinib—CA1—Metabolism—WWTR1—vascular cancer	0.00137	0.00199	CbGpPWpGaD
Nilotinib—KIT—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00136	0.00198	CbGpPWpGaD
Nilotinib—PDGFRA—B Cell Activation—TSC2—vascular cancer	0.00134	0.00196	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD34—vascular cancer	0.00132	0.00192	CbGpPWpGaD
Nilotinib—MAPK14—Insulin Signaling—TSC2—vascular cancer	0.00132	0.00192	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—WWTR1—vascular cancer	0.00131	0.0019	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by FGFR in disease—TSC2—vascular cancer	0.00131	0.0019	CbGpPWpGaD
Nilotinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00131	0.0019	CbGpPWpGaD
Nilotinib—PDGFRB—DAP12 interactions—TSC2—vascular cancer	0.00131	0.0019	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR—TSC2—vascular cancer	0.0013	0.00189	CbGpPWpGaD
Nilotinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00129	0.00187	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00129	0.00187	CbGpPWpGaD
Nilotinib—LYN—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00128	0.00186	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by PDGF—TSC2—vascular cancer	0.00128	0.00186	CbGpPWpGaD
Nilotinib—LCK—Signaling by SCF-KIT—TSC2—vascular cancer	0.00126	0.00183	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD34—vascular cancer	0.00125	0.00182	CbGpPWpGaD
Nilotinib—CA14—Metabolism—HBA1—vascular cancer	0.00124	0.0018	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD34—vascular cancer	0.00123	0.00179	CbGpPWpGaD
Nilotinib—PDGFRB—B Cell Activation—TSC2—vascular cancer	0.00121	0.00176	CbGpPWpGaD
Nilotinib—CA6—Metabolism—HBA1—vascular cancer	0.00121	0.00176	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00121	0.00175	CbGpPWpGaD
Nilotinib—BRAF—Disease—WWTR1—vascular cancer	0.0012	0.00175	CbGpPWpGaD
Nilotinib—CA9—Metabolism—WWTR1—vascular cancer	0.0012	0.00175	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB4—TSC2—vascular cancer	0.00119	0.00173	CbGpPWpGaD
Nilotinib—LYN—B Cell Activation—TSC2—vascular cancer	0.00119	0.00172	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by NGF—TSC2—vascular cancer	0.00116	0.00169	CbGpPWpGaD
Nilotinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00116	0.00169	CbGpPWpGaD
Nilotinib—BRAF—Signaling by NGF—TSC2—vascular cancer	0.00115	0.00167	CbGpPWpGaD
Nilotinib—LCK—Downstream signal transduction—TSC2—vascular cancer	0.00113	0.00165	CbGpPWpGaD
Nilotinib—CA7—Metabolism—HBA1—vascular cancer	0.00113	0.00164	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD34—vascular cancer	0.00113	0.00164	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR—TSC2—vascular cancer	0.00113	0.00164	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB2—TSC2—vascular cancer	0.00112	0.00163	CbGpPWpGaD
Nilotinib—LCK—DAP12 signaling—TSC2—vascular cancer	0.00112	0.00162	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD34—vascular cancer	0.00112	0.00162	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD34—vascular cancer	0.00112	0.00162	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD34—vascular cancer	0.00111	0.00162	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD34—vascular cancer	0.0011	0.00161	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.0011	0.0016	CbGpPWpGaD
Nilotinib—KIT—Disease—WWTR1—vascular cancer	0.0011	0.00159	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00108	0.00156	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—WWTR1—vascular cancer	0.00107	0.00155	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—TSC2—vascular cancer	0.00105	0.00153	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—TSC2—vascular cancer	0.00105	0.00153	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00105	0.00153	CbGpPWpGaD
Nilotinib—CA12—Metabolism—HBA1—vascular cancer	0.00105	0.00152	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—TSC2—vascular cancer	0.00105	0.00152	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—TSC2—vascular cancer	0.00104	0.00151	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—WWTR1—vascular cancer	0.00104	0.00151	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00103	0.0015	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—TSC2—vascular cancer	0.00103	0.00149	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—WWTR1—vascular cancer	0.00102	0.00148	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—TSC2—vascular cancer	0.00099	0.00144	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—TSC2—vascular cancer	0.000972	0.00141	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—WWTR1—vascular cancer	0.000935	0.00136	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—WWTR1—vascular cancer	0.000934	0.00136	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00093	0.00135	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—TSC2—vascular cancer	0.000916	0.00133	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD34—vascular cancer	0.000905	0.00132	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—TSC2—vascular cancer	0.000892	0.0013	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD34—vascular cancer	0.000889	0.00129	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—WWTR1—vascular cancer	0.000851	0.00124	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.000848	0.00123	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—WWTR1—vascular cancer	0.000843	0.00123	CbGpPWpGaD
Nilotinib—CA4—Metabolism—HBA1—vascular cancer	0.000834	0.00121	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—TSC2—vascular cancer	0.00083	0.00121	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—TSC2—vascular cancer	0.000828	0.0012	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—TSC2—vascular cancer	0.000827	0.0012	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD34—vascular cancer	0.000802	0.00117	CbGpPWpGaD
Nilotinib—CA2—Metabolism—HBA1—vascular cancer	0.0008	0.00116	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—TSC2—vascular cancer	0.000797	0.00116	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—WWTR1—vascular cancer	0.000768	0.00112	CbGpPWpGaD
Nilotinib—CA1—Metabolism—HBA1—vascular cancer	0.000767	0.00112	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD34—vascular cancer	0.000759	0.0011	CbGpPWpGaD
Nilotinib—LCK—Disease—WWTR1—vascular cancer	0.00075	0.00109	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—WWTR1—vascular cancer	0.000727	0.00106	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—WWTR1—vascular cancer	0.000717	0.00104	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—TSC2—vascular cancer	0.000716	0.00104	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.00069	0.001	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD34—vascular cancer	0.000684	0.000995	CbGpPWpGaD
Nilotinib—CA9—Metabolism—HBA1—vascular cancer	0.000674	0.00098	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD34—vascular cancer	0.00067	0.000974	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD34—vascular cancer	0.000666	0.000969	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—TSC2—vascular cancer	0.000661	0.000962	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—WWTR1—vascular cancer	0.000655	0.000952	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—WWTR1—vascular cancer	0.000641	0.000932	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD34—vascular cancer	0.000635	0.000923	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—WWTR1—vascular cancer	0.000609	0.000885	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—WWTR1—vascular cancer	0.000608	0.000884	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—TSC2—vascular cancer	0.000596	0.000867	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—TSC2—vascular cancer	0.000573	0.000833	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—TSC2—vascular cancer	0.000564	0.000821	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD34—vascular cancer	0.000549	0.000798	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—TSC2—vascular cancer	0.000542	0.000788	CbGpPWpGaD
Nilotinib—HCK—Immune System—TSC2—vascular cancer	0.000534	0.000776	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—WWTR1—vascular cancer	0.000525	0.000764	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—TSC2—vascular cancer	0.000509	0.00074	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—TSC2—vascular cancer	0.000498	0.000724	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—TSC2—vascular cancer	0.000496	0.000721	CbGpPWpGaD
Nilotinib—HCK—Disease—TSC2—vascular cancer	0.000493	0.000716	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—TSC2—vascular cancer	0.000488	0.00071	CbGpPWpGaD
Nilotinib—BLK—Immune System—TSC2—vascular cancer	0.000483	0.000703	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—TSC2—vascular cancer	0.000483	0.000703	CbGpPWpGaD
Nilotinib—FGR—Immune System—TSC2—vascular cancer	0.000482	0.000701	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—TSC2—vascular cancer	0.000478	0.000695	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—TSC2—vascular cancer	0.000472	0.000686	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—WWTR1—vascular cancer	0.000446	0.000649	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—TSC2—vascular cancer	0.000408	0.000594	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—HBA1—vascular cancer	0.000401	0.000584	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—TSC2—vascular cancer	0.000392	0.00057	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—TSC2—vascular cancer	0.000385	0.00056	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—WWTR1—vascular cancer	0.000378	0.000549	CbGpPWpGaD
Nilotinib—BRAF—Disease—TSC2—vascular cancer	0.000352	0.000512	CbGpPWpGaD
Nilotinib—KIT—Immune System—TSC2—vascular cancer	0.000347	0.000505	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—HBA1—vascular cancer	0.000341	0.000495	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—WWTR1—vascular cancer	0.000329	0.000479	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—TSC2—vascular cancer	0.000329	0.000478	CbGpPWpGaD
Nilotinib—KIT—Disease—TSC2—vascular cancer	0.000321	0.000466	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TSC2—vascular cancer	0.000313	0.000455	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—WWTR1—vascular cancer	0.00031	0.000451	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—WWTR1—vascular cancer	0.000307	0.000447	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TSC2—vascular cancer	0.000304	0.000441	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TSC2—vascular cancer	0.000297	0.000432	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—TSC2—vascular cancer	0.000296	0.000431	CbGpPWpGaD
Nilotinib—LYN—Immune System—TSC2—vascular cancer	0.00029	0.000422	CbGpPWpGaD
Nilotinib—ABL1—Immune System—TSC2—vascular cancer	0.000289	0.00042	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TSC2—vascular cancer	0.000275	0.0004	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TSC2—vascular cancer	0.000273	0.000398	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—HBA1—vascular cancer	0.00025	0.000363	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TSC2—vascular cancer	0.000249	0.000362	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TSC2—vascular cancer	0.000247	0.000359	CbGpPWpGaD
Nilotinib—LCK—Immune System—TSC2—vascular cancer	0.000238	0.000346	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TSC2—vascular cancer	0.000225	0.000327	CbGpPWpGaD
Nilotinib—LCK—Disease—TSC2—vascular cancer	0.000219	0.000319	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TSC2—vascular cancer	0.000213	0.000309	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—HBA1—vascular cancer	0.000211	0.000307	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—WWTR1—vascular cancer	0.000203	0.000295	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TSC2—vascular cancer	0.000192	0.000279	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TSC2—vascular cancer	0.000187	0.000273	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HBA1—vascular cancer	0.000184	0.000268	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TSC2—vascular cancer	0.000178	0.000259	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HBA1—vascular cancer	0.000174	0.000252	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HBA1—vascular cancer	0.000172	0.00025	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TSC2—vascular cancer	0.000154	0.000224	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HBA1—vascular cancer	0.000113	0.000165	CbGpPWpGaD
